Navigation Links
Afid Therapeutics Inc.'s New Anticoagulant Heparin Replacement Passes in Vivo Test

LANSING, Mich., Aug. 19 /PRNewswire/ -- Afid Therapeutics, Inc. announced today that it had completed successful in vitro and in vivo (whole animal) demonstrations of the efficacy of its new "traceless" anticoagulant, which is meant to replace heparin in many applications. The in vivo and some of the in vitro studies were carried out by an independent certified third party laboratory. Heparin is a complex drug, which is used beyond the reach of chemical synthesis and can only be obtained from sources such as the intestines and lungs of pigs and cattle. The manufacture and use of heparin from cattle is banned in the US, Canada and Europe, and the main commercial sources of heparin used in North America and Europe are in China where it is purified from the intestines of pigs. There is a very high degree of variability in activity and preparations are prone to contamination.

Heparin is one of the most widely used drugs. Its many uses include the treatment of acute deep venous thrombosis and pulmonary embolism. It is also used to prevent the occurrence of venous thromboembolism in some patients. Two other important other uses of heparin are as adjuncts in dialysis to prevent clotting and to prevent intravascular coagulation during open heart surgical procedures. Heparin is also used to treat angina and to prevent clotting in i.v. devices. Problems in the use of heparin include bleeding in about 10% of patients and the induction of hypersentivity and osteoporosis. There is an intense effort aimed at finding a replacement for heparin.

The new Afid Therapeutics anticoagulant mimics heparin and is designed to produce only carbohydrates and amino acids when it degrades in the blood stream thus minimizing the risks of side effects. Cell toxicity studies carried out thus far show no effect on the viability of mammalian cells.

"We are very appreciative of the support we have received from these organizations. This has been critical to our success," said Rawle Hollingsworth President and Founder of Afid Therapeutics. "We are preparing for the filing of an NDA in the near future."

Afid Therapeutics Inc. specializes in advanced chemistry based on carbohydrates with a focus on the drug discovery and development areas. In addition to its internal R&D efforts in drug discovery and development, Afid Therapeutics provides advanced chemical intermediates to over 80 pharmaceutical companies and research entities around the world. The company has received critical funding from the MEDC 21st Century Fund, Corn Marketing Program of Michigan, the Ann Arbor Spark and the Western Michigan Biosciences Research Commercialization Center.

The Afid Therapeutics chemistry platform is based on the conversion of plant materials, especially from corn and sugar beet, into advanced drugs and other chemical intermediates.

SOURCE Afid Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android app ... new app features a more intuitive SleepScore™ that rates sleep quality on a 100-point ... SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide an ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
(Date:11/25/2015)... ... , ... Today, Mothers Against Drunk Driving (MADD) learned that the ... the first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol ... National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Endo International ... Rajiv De Silva , President and CEO, will discuss ... Healthcare Conference in New York on ... . Click on Investor Relations, and then the ... prior to the presentation,s start time to visit the site ...
Breaking Medicine Technology: